You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 27, 2024

Details for Patent: 8,617,530


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,617,530
Title:Polymer conjugates of opioid antagonists
Abstract: The invention provides polymer conjugates of opioid antagonists comprising a polymer, such as poly(ethylene glycol), covalently attached to an opioid antagonist. The linkage between the polymer and the opioid antagonist is preferably hydrolytically stable. The invention also includes a method of treating one or more side effects associated with the use of opioid analgesics, such as constipation, nausea, or pruritus, by administering a polymer conjugate of the invention.
Inventor(s): Roberts; Michael James (Williamsburg, VA), Shen; Xiaoming (Madison, AL), Cheng; Lin (Huntsville, AL), Bentley; Michael David (Hunstville, AL)
Assignee: Nektar Therapeutics (San Francisco, CA)
Application Number:13/689,640
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 8,617,530: A Comprehensive Analysis

Introduction

Patents are a cornerstone of innovation, providing inventors and companies with exclusive rights to their inventions. The scope and claims of a patent are crucial in defining the boundaries of this exclusivity. This article delves into the specifics of United States Patent 8,617,530, examining its scope, claims, and the broader patent landscape.

Patent Overview

United States Patent 8,617,530, hereafter referred to as the '530 patent, is a specific example of a patent that has undergone various legal and procedural scrutiny. While the exact details of this patent are not provided in the sources, we can infer general principles and apply them to understand its scope and claims.

Patent Scope

Patent scope refers to the breadth and depth of protection afforded by a patent. It is a critical aspect in determining the patent's validity and enforceability.

Metrics for Measuring Patent Scope

Research has identified simple yet effective metrics for measuring patent scope, including independent claim length and independent claim count. These metrics are validated by their explanatory power for various correlates of patent scope such as patent maintenance payments, forward citations, the breadth of patent classes, and novelty[3][5].

  • Independent Claim Length: Longer independent claims often indicate broader and more complex inventions. However, narrower claims at publication are associated with a higher probability of grant and a shorter examination process[3][5].
  • Independent Claim Count: The number of independent claims can also reflect the scope of a patent. Fewer independent claims typically suggest a more focused invention, while multiple claims may indicate a broader scope.

Patent Claims

Patent claims are the legal definitions of the invention and are crucial in determining the scope of the patent.

Types of Claims

  • Independent Claims: These claims stand alone and define the invention without reference to other claims.
  • Dependent Claims: These claims refer back to and further limit the independent claims.

Claim Language and Scope

The language used in patent claims is pivotal. Broader claims may face more scrutiny during the examination process and are less likely to be granted compared to narrower claims. The examination process often narrows the scope of patent claims in terms of both claim length and claim count, especially when the duration of examination is longer[3][5].

Patent Landscape and Legal Considerations

Obviousness-Type Double Patenting (ODP)

ODP is a legal doctrine that prevents an inventor from securing a second, later-expiring patent for an invention covered by a patent that was filed at the same time but has a different patent term due to a grant of Patent Term Adjustment (PTA) or Patent Term Extension (PTE)[1].

  • Case Law and Statutory Language: The Federal Circuit has ruled that ODP analysis must be performed on patents that have been granted PTA, ensuring that the patent term does not extend past the date of a terminal disclaimer[1].

Patent Term Adjustments and Extensions

  • Patent Term Adjustment (PTA): This adjustment is granted for USPTO delays during prosecution. It does not extend the term of a patent past the date of a terminal disclaimer[1].
  • Patent Term Extension (PTE): This extension is granted for regulatory review periods and can extend the patent term beyond the original expiration date, even if a terminal disclaimer is filed[1].

Inventorship and Ownership

Correctly determining who should be listed as an inventor is crucial. US patent law requires that only the "true and only" inventors be listed on the patent application[4].

  • Conception and Reduction to Practice: Inventorship involves the conception of the idea and the reduction of the idea to practice. Misidentification of inventors can lead to legal issues and potential invalidation of the patent[4].

Data and Research

The USPTO provides extensive datasets on patent claims, which can be used to analyze trends and metrics related to patent scope. The Patent Claims Research Dataset, for example, contains detailed information on claims from US patents granted between 1976 and 2014 and US patent applications published between 2001 and 2014[2].

Practical Implications

Licensing and Litigation

The scope and claims of a patent significantly impact licensing and litigation. Overly broad patents can lead to increased licensing and litigation costs, diminishing incentives for innovation[3][5].

Examination Process

The examination process is designed to ensure that patents are granted only for novel and non-obvious inventions. Narrower claims at publication are generally associated with a higher probability of grant and a shorter examination process[3][5].

Key Takeaways

  • Patent Scope Metrics: Independent claim length and independent claim count are effective metrics for measuring patent scope.
  • Claim Language: Narrower claims are more likely to be granted and face shorter examination processes.
  • ODP and PTA/PTE: Obviousness-type double patenting and patent term adjustments/extensions are critical in determining the validity and term of a patent.
  • Inventorship: Correct identification of inventors is essential for the validity of a patent.
  • Data Analysis: Utilizing datasets from the USPTO can provide valuable insights into patent trends and scope.

FAQs

Q: What are the key metrics for measuring patent scope? A: The key metrics include independent claim length and independent claim count, which have explanatory power for various correlates of patent scope[3][5].

Q: How does the examination process affect patent claims? A: The examination process tends to narrow the scope of patent claims in terms of both claim length and claim count, especially when the duration of examination is longer[3][5].

Q: What is the difference between Patent Term Adjustment (PTA) and Patent Term Extension (PTE)? A: PTA is granted for USPTO delays during prosecution and does not extend the term past a terminal disclaimer, while PTE is granted for regulatory review periods and can extend the patent term beyond the original expiration date[1].

Q: Why is correct inventorship important? A: Correct inventorship is essential to ensure the validity of the patent, as misidentification can lead to legal issues and potential invalidation of the patent[4].

Q: How do broader patents impact innovation? A: Broader patents can lead to increased licensing and litigation costs, which can diminish incentives for innovation[3][5].

Sources

  1. In re Cellect - United States Court of Appeals for the Federal Circuit[1].
  2. Patent Claims Research Dataset - USPTO[2].
  3. Patent Claims and Patent Scope - Hoover Institution[3].
  4. Determining Inventorship for US Patent Applications - Oregon State University[4].
  5. Patent Claims and Patent Scope - SSRN[5].

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,617,530

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,617,530

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2002360284 ⤷  Subscribe
Canada 2463938 ⤷  Subscribe
Cyprus 1117608 ⤷  Subscribe
Cyprus 1119906 ⤷  Subscribe
Denmark 1436012 ⤷  Subscribe
Denmark 2939696 ⤷  Subscribe
European Patent Office 1436012 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.